Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'TARDIVE-DYSKINESIA' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 1090 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Haut, F; Clos, S
      Acute akathisia and sodium valproate

      INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE
    2. Procyshyn, RM; Flynn, S
      Discharge prescribing practices: Comparing a research ward to general treatment wards

      INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE
    3. Rybakowski, JK; Borkowska, A; Czerski, PM; Hauser, J
      Dopamine D3 receptor (DRD3) gene polymorphism is associated with the intensity of eye movement disturbances in schizophrenic patients and healthy subjects

      MOLECULAR PSYCHIATRY
    4. Govoni, S; Racchi, M; Masoero, E; Zamboni, M; Ferini-Strambi, L
      Extrapyramidal symptoms and antidepressant drugs: neuropharmacological aspects of a frequent interaction in the elderly

      MOLECULAR PSYCHIATRY
    5. Segman, RH; Heresco-Levy, U; Finkel, B; Goltser, T; Shalem, R; Schlafman, M; Dorevitch, A; Yakir, A; Greenberg, D; Lerner, A; Lerer, B
      Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia

      MOLECULAR PSYCHIATRY
    6. Basile, VS; Ozdemir, V; Masellis, M; Meltzer, HY; Lieberman, JA; Potkin, SG; Macciardi, FM; Petronis, A; Kennedy, JL
      Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia

      MOLECULAR PSYCHIATRY
    7. Lovlie, R; Thara, R; Padmavathi, R; Steen, VM; McCreadie, RG
      Ser9Gly dopamine D3 receptor polymorphism and spontaneous dyskinesia in never-medicated schizophrenic patients

      MOLECULAR PSYCHIATRY
    8. Herken, H; Uz, E; Ozyurt, H; Sogut, S; Virit, O; Akyol, O
      Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation ape increased in different forms of schizophrenia

      MOLECULAR PSYCHIATRY
    9. Oosthuizen, P; Emsley, RA
      First-episode psychosis: lessons from 15 years of research

      PRIMARY CARE PSYCHIATRY
    10. Wooten, GF
      Anatomy and function of dopamine receptors: understanding the pathophysiology of fluctuations in Parkinson's disease

      PARKINSONISM & RELATED DISORDERS
    11. Krack, P; Vercueil, L
      Review of the functional surgical treatment of dystonia

      EUROPEAN JOURNAL OF NEUROLOGY
    12. Warren, BH; Crews, CK; Schulte, MM
      Managing patients with diabetes mellitus and mental health problems - Administrative and clinical challenges

      DISEASE MANAGEMENT & HEALTH OUTCOMES
    13. Desai, HD; Seabolt, J; Jann, MW
      Smoking in patients receiving psychotropic medications - A pharmacokineticperspective

      CNS DRUGS
    14. Yao, JK; Reddy, RD; van Kammen, DP
      Oxidative damage and schizophrenia - An overview of the evidence and its therapeutic implications

      CNS DRUGS
    15. Arranz, MJ; Mancama, D; Kerwin, RW
      Neurotransmitter receptor variants and their influence on antipsychotic treatment (Review)

      INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
    16. Kennedy, A; Jain, S; Vinogradov, S
      Atypical antipsychotics for schizophrenia: Their collective role and comparative profiles

      FORMULARY
    17. Schneider, LS; Tariot, PN; Lyketsos, CG; Dagerman, KS; Davis, KL; Davis, S; Hsiao, JK; Jeste, DV; Katz, IR; Olin, JT; Pollock, BG; Rabins, PV; Rosenheck, RA; Small, GW; Lebowitz, B; Lieberman, JA
      National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) - Alzheimer disease trial methodology

      AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
    18. Madhusoodanan, S
      Introduction - Antipsychotic treatment of behavioral and psychological symptoms of dementia in geropsychiatric patients

      AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
    19. Farver, DK; Khan, MH
      Zolpidem for antipsychatic-induced parkinsonism

      ANNALS OF PHARMACOTHERAPY
    20. Bryden, KE; Carrey, NJ; Kutcher, SP
      Update and recommendations for the use of antipsychotics in early-onset psychoses

      JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY
    21. Naidu, PS; Kulkarni, SK
      Excitatory mechanisms in neuroleptic-induced vacuous chewing movements (VCMs): possible involvement of calcium and nitric oxide

      BEHAVIOURAL PHARMACOLOGY
    22. Collier, DA; Osborne, S; Munro, J; Kerwin, RW
      Pharmacogenetic methods in schizophrenia

      INTERNATIONAL REVIEW OF PSYCHIATRY
    23. Bullock, R
      Drug treatment in dementia

      CURRENT OPINION IN PSYCHIATRY
    24. Malhotra, AK
      The genetics of schizophrenia

      CURRENT OPINION IN PSYCHIATRY
    25. Kane, JM
      Extrapyramidal side effects are unacceptable

      EUROPEAN NEUROPSYCHOPHARMACOLOGY
    26. Chengappa, KNR; Levine, J; Rathore, D; Parepally, H; Atzert, R
      Long-term effects of topiramate on bipolar mood instability, weight changeand glycemic control: a case-series

      EUROPEAN PSYCHIATRY
    27. Bergiannaki, JD; Hatzimanolis, J; Liappas, J; Sakkas, PN; Stefanis, CN
      Relapse prevention in schizophrenia: attitudes of neurologists-psychiatrists

      EUROPEAN PSYCHIATRY
    28. Schulze, TG; Muller, DJ; Krauss, H; Marwinski, K; Maroldt, AO; Fernandez, ANY; Fimmers, R; Held, T; Maier, W; Nothen, MM; Rietschel, M
      Affective symptomatology in schizophrenia: a risk factor for tardive dyskinesia?

      EUROPEAN PSYCHIATRY
    29. Salzman, C
      Treatment of the agitation of late-life psychosis and Alzheimer's disease

      EUROPEAN PSYCHIATRY
    30. McGlashan, TH
      Psychosis treatment prior to psychosis onset: ethical issues

      SCHIZOPHRENIA RESEARCH
    31. Peet, M; Brind, J; Ramchand, CN; Shah, S; Vankar, GK
      Two double-blind placebo-controlled pilot studies of eicosapentaenoic acidin the treatment of schizophrenia

      SCHIZOPHRENIA RESEARCH
    32. Quinn, J; Meagher, D; Murphy, P; Kinsella, A; Mullaney, J; Waddington, JL
      Vulnerability to involuntary movements over a lifetime trajectory of schizophrenia approaches 100%, in association with executive (frontal) dysfunction

      SCHIZOPHRENIA RESEARCH
    33. Dahmen, N; Muller, MJ; Germeyer, S; Rujescu, D; Anghelescu, I; Hiemke, C; Wetzel, H
      Genetic polymorphisms of the dopamine D-2 and D-3 receptor and neurolepticdrug effects in schizophrenic patients

      SCHIZOPHRENIA RESEARCH
    34. Salyers, MP; Mueser, KT
      Social functioning, psychopathology, and medication side effects in relation to substance use and abuse in schizophrenia

      SCHIZOPHRENIA RESEARCH
    35. Srinivasan, TN; Thara, R; Padmavathi, R; McCreadie, RG
      Relationship of extrapyramidal symptoms to age at onset and drug treatmentin middle-aged and elderly schizophrenic patients

      SCHIZOPHRENIA RESEARCH
    36. Bodfish, JW; Parker, DE; Lewis, MH; Sprague, RL; Newell, KM
      Stereotypy and motor control: Differences in the postural stability dynamics of persons with stereotyped and dyskinetic movement disorders

      AMERICAN JOURNAL ON MENTAL RETARDATION
    37. Lindamer, LA; Lohr, JB; Caligiuri, MP; Jeste, DV
      Relationship of gender and age at onset of schizophrenia to severity of dyskinesia

      JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES
    38. Barbaccia, ML; Affricano, D; Purdy, RH; Maciocco, E; Spiga, F; Biggio, G
      Clozapine, but not haloperidol, increases brain concentrations of neuroactive steroids in the rat

      NEUROPSYCHOPHARMACOLOGY
    39. Scheepers, FE; de Wied, CCG; Pol, HEH; van de Flier, W; van der Linden, JA; Kahn, RS
      The effect of clozapine on caudate nucleus volume in schizophrenic patients previously treated with typical antipsychotics

      NEUROPSYCHOPHARMACOLOGY
    40. Malone, RP; Cater, J; Sheikh, RM; Choudhury, MS; Delaney, MA
      Olanzapine versus haloperidol in children with autistic disorder: An open pilot study

      JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY
    41. Sakai, K; Gao, XM; Hashimoto, T; Tamminga, CA
      Traditional and new antipsychotic drugs differentially alter neurotransmission markers in basal ganglia-thalamocortical neural pathways

      SYNAPSE
    42. Roberts, RC
      Effect of chronic olanzapine treatment on striatal synaptic organization

      SYNAPSE
    43. Grimm, JW; Chapman, MA; Zahm, DS; See, RE
      Decreased choline acetyltransferase immunoreactivity in discrete striatal subregions following chronic haloperidol in rats

      SYNAPSE
    44. Hansen, L
      A critical review of akathisia, and its possible association with suicidalbehaviour

      HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL
    45. Schultz, SK; Ellingrod, V; Fleming, FW; Andreasen, NC
      The association between risk factors for tardive dyskinesia and phenylalanine-induced abnormal movements in schizophrenia

      HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL
    46. Tariot, PN; Ryan, JM; Porsteinsson, AP; Loy, R; Schneider, LS
      Pharmacologic therapy for behavioral symptoms of Alzheimer's disease

      CLINICS IN GERIATRIC MEDICINE
    47. Mahant, PR; Stacy, MA
      Movement disorders and normal aging

      NEUROLOGIC CLINICS
    48. Higgins, DS
      Chorea and its disorders

      NEUROLOGIC CLINICS
    49. Friedlander, R; Lazar, S; Klancnik, J
      Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities

      CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE
    50. Ahmed, AG; Heigh, LM; Ramachandran, KV
      Polydipsia, psychosis, and familial psychopathology

      CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE
    51. Procyshyn, RM; Kennedy, NB; Tse, G; Thompson, B
      Antipsychotic polypharmacy: A survey of discharge prescriptions from a tertiary care psychiatric institution

      CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE
    52. Rascol, O; Fabre, N
      Dyskinesia: L-dopa-induced and tardive dyskinesia

      CLINICAL NEUROPHARMACOLOGY
    53. Miyata, S; Hamamura, T; Yoshinaga, J; Nakamura, Y; Imamura, T; Hikiji, A; Kuroda, S
      Amelioration of frozen gait by tandospirone, a serotonin 1A agonist, in a patient with pure akinesia developing resistance to L-threo-3,4-dihydroxyphenylserine

      CLINICAL NEUROPHARMACOLOGY
    54. Sutcher, H
      Prosthetic dentistry in the treatment of movement disorders: dyskinesias and other neurological abnormalities

      MEDICAL HYPOTHESES
    55. Bayas, A; Kornhuber, J; Naumann, M
      Atypical neuroleptics and new antidepressants in the treatment of neurological disorders

      AKTUELLE NEUROLOGIE
    56. Iwahashi, K; Anemo, K; Nakamura, K; Fukunishi, I; Igarashi, K
      Analysis of the metabolism of haloperidol and its neurotoxic pyridinium metabolite in patients with, drug-induced parkinsonism

      NEUROPSYCHOBIOLOGY
    57. Liao, DL; Yeh, YC; Chen, HM; Chen, H; Hong, CJ; Tsai, SJ
      Association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients

      NEUROPSYCHOBIOLOGY
    58. Garcia-Barcelo, MM; Lam, LCW; Ungvari, GS; Lam, VKL; Tang, WK
      Dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients

      JOURNAL OF NEURAL TRANSMISSION
    59. Fukasawa, T; Takahashi, M; Otani, K
      A successful clonazepam treatment without tolerance in a patient with spontaneous oral dyskinesia

      PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
    60. Mahadik, SP; Evans, D; Lal, H
      Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia

      PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
    61. Sethi, KD
      Movement disorders induced by dopamine blocking agents

      SEMINARS IN NEUROLOGY
    62. Wassef, AA; Hafiz, NG; Hampton, D; Molloy, M
      Divalproex sodium augmentation of haloperidol in hospitalized patients with schizophrenia: Clinical and economic implications

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    63. Zhang, XY; Zhou, DF; Su, JM; Zhang, PY
      The effect of extract of ginkgo biloba added to haloperidol on superoxide dismutase in inpatients with chronic schizophrenia

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    64. Mehta, A; Bot, G; Reisine, T; Chesselet, MF
      Endomorphin-1: Induction of motor behavior and lack of receptor desensitization

      JOURNAL OF NEUROSCIENCE
    65. Uzun, O; Cansever, A; Ozsahin, A
      A case of relapsed tardive dyskinesia due to clozapine dose reduction

      INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    66. Lam, LCW; Garcia-Barcelo, MM; Ungvari, GS; Tang, WK; Lam, VKL; Kwong, SL; Lau, BST; Kwong, PPK; Waye, MMY; Chiu, HFK
      Cytochrome P450 2D6 genotyping and association with tardive dyskinesia in Chinese schizophrenic patients

      PHARMACOPSYCHIATRY
    67. Tohen, M; Zhang, F; Taylor, CC; Burns, P; Zarate, C; Sanger, T; Tollefson, G
      A meta-analysis of the use of typical antipsychotic agents in bipolar disorder

      JOURNAL OF AFFECTIVE DISORDERS
    68. Ozdemir, V; Basile, VS; Masellis, M; Kennedy, JL
      Pharmacogenetic assessment of antipsychotic-induced movement disorders: contribution of the dopamine D3 receptor and cytochrome P450 1A2 genes

      JOURNAL OF BIOCHEMICAL AND BIOPHYSICAL METHODS
    69. Sajatovic, M; Brescan, DW; Perez, DE; DiGiovanni, SK; Hattab, H; Ray, JB; Bingham, CR
      Quetiapine alone and added to a mood stabilizer for serious mood disorders

      JOURNAL OF CLINICAL PSYCHIATRY
    70. Vieta, E; Herraiz, M; Fernandez, A; Gasto, C; Benabarre, A; Colom, F; Martinez-Aran, A; Reinares, M
      Efficacy and safety of risperidone in the treatment of schizoaffective disorder: Initial results from a large, multicenter surveillance study

      JOURNAL OF CLINICAL PSYCHIATRY
    71. Sanger, TM; Grundy, SL; Gibson, PJ; Namjoshi, MA; Greaney, MG; Tohen, MF
      Long-term olanzapine therapy in the treatment of bipolar I disorder: An open-label continuation phase study

      JOURNAL OF CLINICAL PSYCHIATRY
    72. Budman, CL; Gayer, A; Lesser, M; Shi, QH; Bruun, RD
      An open-label study of the treatment efficacy of olanzapine for Tourette'sdisorder

      JOURNAL OF CLINICAL PSYCHIATRY
    73. Wirshing, WC
      Movement disorders associated with neuroleptic treatment

      JOURNAL OF CLINICAL PSYCHIATRY
    74. De Deyn, PP; Wirshing, WC
      Scales to assess efficacy and safety of pharmacologic agents in the treatment of behavioral and psychological symptoms of dementia

      JOURNAL OF CLINICAL PSYCHIATRY
    75. Mintzer, JE
      Underlying mechanisms of psychosis and aggression in patients with Alzheimer's disease

      JOURNAL OF CLINICAL PSYCHIATRY
    76. Tune, LE
      Risperidone for the treatment of behavioral and psychological symptoms of dementia

      JOURNAL OF CLINICAL PSYCHIATRY
    77. Kinon, BJ; Roychowdhury, SM; Milton, DR; Hill, AL
      Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia

      JOURNAL OF CLINICAL PSYCHIATRY
    78. Hori, H; Ohmori, O; Shinkai, T; Kojima, H; Nakamura, J
      Association between three functional polymorphisms of dopamine D2 receptorgene and tardive dyskinesia in schizophrenia

      AMERICAN JOURNAL OF MEDICAL GENETICS
    79. Ozdemir, V; Shear, NH; Kalow, W
      What will be the role of pharmacogenetics in evaluating drug safety and minimising adverse effects?

      DRUG SAFETY
    80. Phillips, KA; Veenstra, DL; Oren, E; Lee, JK; Sadee, W
      Potential role of pharmacogenomics in reducing adverse drug reactions - A systematic review

      JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
    81. Mehta, A; Eberle-Wang, K; Chesselet, MF
      Increased m-CPP-induced oral dyskinesia after lesion of serotonergic neurons

      PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
    82. Kapur, S; Remington, G
      Atypical antipsychotics: New directions and new challenges in the treatment of schizophrenia

      ANNUAL REVIEW OF MEDICINE
    83. Agarwal, V; Sitholey, P; Kumar, S; Prasad, M
      Double-blind, placebo-controlled trial of clonidine in hyperactive children with mental retardation

      MENTAL RETARDATION
    84. Jahnel, M
      H.A. Huntington's disease relevant differential diagnosis in geropsychiatric patients?

      NERVENARZT
    85. Goff, DC; Heckers, S; Freudenreich, O
      Schizophrenia

      MEDICAL CLINICS OF NORTH AMERICA
    86. Sutor, B; Rummans, TA; Smith, GE
      Assessment and management of behavioral disturbances in nursing home patients with dementia

      MAYO CLINIC PROCEEDINGS
    87. Henry, B; Fox, SH; Crossman, AR; Brotchie, JM
      mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease

      EXPERIMENTAL NEUROLOGY
    88. Rodriguez, JJ; Garcia, DR; Nakabeppu, Y; Pickel, VM
      Enhancement of laminar FosB expression in frontal cortex of rats receivinglong chronic clozapine administration

      EXPERIMENTAL NEUROLOGY
    89. Naidu, PS; Kulkarni, SK
      Possible involvement of prostaglandins in haloperidol-induced orofacial dyskinesia in rats

      EUROPEAN JOURNAL OF PHARMACOLOGY
    90. Bymaster, FP; Falcone, JF; Bauzon, D; Kennedy, JS; Schenck, K; DeLapp, NW; Cohen, ML
      Potent antagonism of 5-HT3 and 5-HT6 receptors by olanzapine

      EUROPEAN JOURNAL OF PHARMACOLOGY
    91. Naidu, PS; Kulkarni, SK
      Effect of 5-HT1A and 5-HT2A/2C receptor modulation on neuroleptic-induced vacuous chewing movements

      EUROPEAN JOURNAL OF PHARMACOLOGY
    92. Naidu, PS; Kulkarni, SK
      Reversal of neuroleptic-induced orofacial dyskinesia by 5-HT3 receptor antagonists

      EUROPEAN JOURNAL OF PHARMACOLOGY
    93. Cookson, J
      Use of antipsychotic drugs and lithium in mania

      BRITISH JOURNAL OF PSYCHIATRY
    94. Raghavendra, V; Naidu, PS; Kulkarni, SK
      Reversal of reserpine-induced vacuous chewing movements in rats by melatonin: involvement of peripheral benzodiazepine receptors

      BRAIN RESEARCH
    95. Tan, EC; Chong, SA; Mahendran, R; Dong, F; Tan, CH
      Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor

      BIOLOGICAL PSYCHIATRY
    96. Maurer, I; Volz, HP
      Cell-mediated side effects of psychopharmacological treatment

      ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH
    97. Glazer, WM; Woods, SW
      Should sisyphus have taken melatonin?

      ARCHIVES OF GENERAL PSYCHIATRY
    98. Heaton, RK; Gladsjo, JA; Palmer, BW; Kuck, J; Marcotte, TD; Jeste, DV
      Stability and course of neuropsychological deficits in schizophrenia

      ARCHIVES OF GENERAL PSYCHIATRY
    99. Chakos, M; Lieberman, J; Hoffman, E; Bradford, D; Sheitman, B
      Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: A review and meta-analysis of randomized trials

      AMERICAN JOURNAL OF PSYCHIATRY
    100. Egan, MF; Hyde, TM; Bonomo, JB; Mattay, VS; Bigelow, LB; Goldberg, TE; Weinberger, DR
      Relative risk of neurological signs in siblings of patients with schizophrenia

      AMERICAN JOURNAL OF PSYCHIATRY


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 12/12/19 alle ore 15:30:22